Heron Therapeutics (NASDAQ:HRTX - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Friday.
Separately, Needham & Company LLC reiterated a "buy" rating and set a $4.00 target price on shares of Heron Therapeutics in a research report on Friday, April 11th.
Read Our Latest Stock Report on Heron Therapeutics
Heron Therapeutics Price Performance
HRTX traded up $0.10 during trading on Friday, reaching $2.10. 1,707,789 shares of the stock were exchanged, compared to its average volume of 2,240,458. The business's 50 day moving average price is $2.02 and its two-hundred day moving average price is $1.86. The company has a market capitalization of $320.38 million, a price-to-earnings ratio of -11.67 and a beta of 1.15. Heron Therapeutics has a 1 year low of $1.04 and a 1 year high of $3.93.
Heron Therapeutics (NASDAQ:HRTX - Get Free Report) last posted its earnings results on Tuesday, May 6th. The biotechnology company reported $0.01 EPS for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $38.90 million for the quarter, compared to analysts' expectations of $37.08 million. On average, analysts anticipate that Heron Therapeutics will post -0.13 EPS for the current year.
Institutional Trading of Heron Therapeutics
Institutional investors have recently bought and sold shares of the company. RFP Financial Group LLC acquired a new stake in shares of Heron Therapeutics during the first quarter valued at $26,000. Nicolet Advisory Services LLC acquired a new stake in shares of Heron Therapeutics during the fourth quarter valued at $25,000. Valeo Financial Advisors LLC boosted its stake in shares of Heron Therapeutics by 34.1% during the first quarter. Valeo Financial Advisors LLC now owns 18,152 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 4,619 shares during the last quarter. Argent Advisors Inc. acquired a new stake in shares of Heron Therapeutics during the fourth quarter valued at $31,000. Finally, Focus Partners Wealth acquired a new stake in shares of Heron Therapeutics during the fourth quarter valued at $31,000. 80.01% of the stock is currently owned by hedge funds and other institutional investors.
About Heron Therapeutics
(
Get Free Report)
Heron Therapeutics, Inc, a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
Featured Stories
Before you consider Heron Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Heron Therapeutics wasn't on the list.
While Heron Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
